New SightGlass Vision Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology™ Spectacle Lenses at ARVO 2023

Studies Presented at ARVO 2023 Analyze and Evaluate Multiple Performance Characteristics, Including Positive 42-Month CYPRESS Axial Length and SER Outcomes

LOS ALTOS, CALIF., April 23, 2023 – SightGlass Vision today announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics TechnologyTM spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Meeting in New Orleans.

Most prominent is the reporting of 42-month data from the company’s pivotal CYPRESS study extension. Results reinforced the safety and efficacy of Diffusion Optics TechnologyTM spectacle lenses in children aged 6–10 at the study’s start.1 The latest investigation re- enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial to generate six additional months of data. Outcomes again demonstrated statistically significant improvements in axial length (AL) and cycloplegic spherical equivalent refraction (cSER) between the test and control groups.

Separate work calculated age-independent myopia AL growth to evaluate Diffusion Optics TechnologyTM spectacle lens efficacy.2 Because AL growth occurs even in persistently emmetropic eyes as a child develops and is most rapid before preadolescence, deriving an age-adjusted measure is valuable for clinicians and researchers. Physiological AL growth was determined based on age-matched emmetropic eye growth data from the Orinda Longitudinal Study of Myopia3, then compared to AL growth observed in the original three- year CYPRESS study. Children in the test lens group showed 0.23 mm (73%, p=0.003) less pathological AL change than the control group (test: 0.08 ± 0.06 mm; control: 0.31 ± 0.05 mm).

“The extensive and rigorous science we are communicating at ARVO 2023 demonstrates the depth of our commitment to advancing myopia control, while also building additional confidence in the efficacy, safety, and overall performance of Diffusion Optics TechnologyTM spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision.

In addition to the featured CYPRESS presentations, SightGlass Vision and its research partners will display several scientific posters at the meeting. A study from the Centre for Ocular Research & Education (CORE) shows that Diffusion Optics TechnologyTM spectacle lenses have no significant effect on accommodative lag after short-term wear.4 Work from Indiana University suggests that Diffusion Optics TechnologyTM contrast-reducing micro-dots do not limit high quality spatial details and good visual performance5, while another Indiana investigation concludes that wearers are unlikely to notice substantial contrast decreases when looking through the spectacle lens treatment zone.6 A SightGlass team also examined the effect of social restrictions during the COVID-19 pandemic on myopia progression in North American children who participated in the CYPRESS study.7

Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to soften contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1ᣟ2ᣟ8ᣟ9ᣟ10 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.

For more information, visit SightGlassVision.com.

About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States